tradingkey.logo

Theriva Biologics Announces Primary Endpoints For Efficacy And Safety Achieved In VIRAGE Phase 2B Clinical Trial Of VCN-01 With Gemcitabine/NAB-Paclitaxel In Newly-Diagnosed Metastatic Pancreatic Cancer Patients

ReutersMay 7, 2025 11:11 AM

- Theriva Biologics Inc TOVX.A:

  • THERIVA™ BIOLOGICS ANNOUNCES PRIMARY ENDPOINTS FOR EFFICACY AND SAFETY ACHIEVED IN VIRAGE PHASE 2B CLINICAL TRIAL OF VCN-01 WITH GEMCITABINE/NAB-PACLITAXEL IN NEWLY-DIAGNOSED METASTATIC PANCREATIC CANCER PATIENTS

  • THERIVA BIOLOGICS INC - VCN-01 RECEIVES ORPHAN DRUG AND FAST TRACK DESIGNATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI